The median progression-free survival (PFS), or the time between the start of treatment and the onset of cancer, of various KRAS mutations has also been studied, with a median PFS of 15.57 weeks and overall survival (OS) of 18.64 weeks for KRAS G12C [34,46]. Here, KRAS is linked to cancer.